Sandoz (SDZNY) has completed the acquisition of the US biosimilar CIMERLI from Coherus BioSciences (CHRS), ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product launches. Keren Haruvi, President Sandoz North America said: “Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines. With the addition of CIMERLI to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.” CIMERLI is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss, which ranks among the top 10 causes of disability in the United States. Sandoz and Coherus entered into an agreement in January 2024 through which Sandoz agreed to acquire the full CIMERLI business for an upfront cash purchase price of USD 170 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SDZNY:
- Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
- Sandoz U.S. subsidiaries resolve generic drug antitrust class action litigation
- Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
- Sandoz receives Health Canada approval for Jubbonti
- Sandoz downgraded to Equal Weight from Overweight at Morgan Stanley
